9 results on '"Cantón, Rafael"'
Search Results
2. Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility.
- Author
-
Kahlmeter, Gunnar, Cantón, Rafael, Giske, Christian G., and Turnidge, John
- Subjects
- *
COMMON sense , *ITRACONAZOLE , *MICROBIAL sensitivity tests , *ANTIFUNGAL agents - Abstract
National dissemination of EUCAST guidelines is a shared responsibility In preparation for all major decisions, EUCAST encourages National AST Committees (NACs) to discuss and inform national colleagues and to respond to consultations - all NACs were addressed, including the Swiss NAC - and their response will be among the others. It is later introduced by the Clinical and Laboratory Standards Institute (CLSI), primarily for antifungal susceptibility testing, but later also for a few antibacterial agents: cefepime, CLSI M100-S14 (2014) and subsequently ceftaroline and daptomycin. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
3. Pseudomonasaeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group.
- Author
-
Oliver, Antonio, Rojo-Molinero, Estrella, Arca-Suarez, Jorge, Beşli, Yeşim, Bogaerts, Pierre, Cantón, Rafael, Cimen, Cansu, Croughs, Peter D., Denis, Olivier, Giske, Christian G., Graells, Tíscar, Daniel Huang, Te-Din, Iorga, Bogdan I., Karatuna, Onur, Kocsis, Béla, Kronenberg, Andreas, López-Causapé, Carla, Malhotra-Kumar, Surbhi, Martínez, Luis Martínez, and Mazzariol, Annarita
- Subjects
- *
PSEUDOMONAS aeruginosa , *MEDICAL microbiology , *DRUG resistance in microorganisms , *COMMUNICABLE diseases , *WHOLE genome sequencing , *RESEARCH personnel - Abstract
Pseudomonas aeruginosa , a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital-acquired and chronic infections associated with significant morbidity and mortality. This growing threat results from the extraordinary capacity of P. aeruginosa to develop antimicrobial resistance through chromosomal mutations, the increasing prevalence of transferable resistance determinants (such as the carbapenemases and the extended-spectrum β-lactamases), and the global expansion of epidemic lineages. The general objective of this initiative is to provide a comprehensive update of P. aeruginosa resistance mechanisms, especially for the extensively drug-resistant (XDR)/difficult-to-treat resistance (DTR) international high-risk epidemic lineages, and how the recently approved β-lactams and β-lactam/β-lactamase inhibitor combinations may affect resistance mechanisms and the definition of susceptibility profiles. To address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases launched the 'Improving Surveillance of Antibiotic-Resistant Pseudomonas aeruginosa in Europe (ISARPAE)' initiative in 2022, supported by the Joint programming initiative on antimicrobial resistance network call and included a panel of over 40 researchers from 18 European Countries. Thus, a ESGARS-ISARPAE position paper was designed and the final version agreed after four rounds of revision and discussion by all panel members. To provide an update on (a) the emerging resistance mechanisms to classical and novel anti-pseudomonal agents, with a particular focus on β-lactams, (b) the susceptibility profiles associated with the most relevant β-lactam resistance mechanisms, (c) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles, and (d) the globally expanding XDR/DTR high-risk lineages and their association with transferable resistance mechanisms. The evidence presented herein can be used for coordinated epidemiological surveillance and decision making at the European and global level. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA).
- Author
-
Paniagua-García, María, Bravo-Ferrer, Jose M., Pérez-Galera, Salvador, Kostyanev, Tomislav, de Kraker, Marlieke E.A., Feifel, Jan, Palacios-Baena, Zaira R., Schotsman, Joost, Cantón, Rafael, Daikos, George L., Carevic, Biljana, Dragovac, Gorana, Tan, Lionel K., Raka, Lul, Hristea, Adriana, Viale, Pierluigi, Akova, Murat, Cano, Ángela, Reguera, Jose María, and Bartoloni, Alessandro
- Subjects
- *
URINARY tract infections , *COHORT analysis , *INTRA-abdominal infections , *HOSPITAL wards , *MORTALITY - Abstract
To assess the mortality attributable to infections caused by carbapenem-resistant Enterobacterales (CRE) and to investigate the effect of clinical management on differences in observed outcomes in a multinational matched cohort study. A prospective matched-cohorts study (NCT02709408) was performed in 50 European hospitals from March 2016 to November 2018. The main outcome was 30-day mortality with an active post-discharge follow-up when applied. The CRE cohort included patients with complicated urinary tract infections, complicated intra-abdominal infections, pneumonia, or bacteraemia from other sources because of CRE. Two control cohorts were selected: patients with infection caused by carbapenem-susceptible Enterobacterales (CSE) and patients without infection. Matching criteria included type of infection for the CSE group, hospital ward of CRE detection, and duration of hospital admission up to CRE detection. Multivariable and stratified Cox regression was applied. The cohorts included 235 patients with CRE infection, 235 patients with CSE infection, and 705 non-infected patients. The 30-day mortality (95% CI) was 23.8% (18.8–29.6), 10.6% (7.2–15.2), and 8.4% (6.5–10.6), respectively. The difference in 30-day mortality rates between patients with CRE infection when compared with patients with CSE infection was 13.2% (95% CI, 6.3–20.0), (HR, 2.57; 95% CI, 1.55–4.26; p < 0.001), and 15.4% (95% CI, 10.5–20.2) when compared with non-infected patients (HR, 3.85; 95% CI, 2.57–5.77; p < 0.001). The population attributable fraction for 30-day mortality for CRE vs. CSE was 19.28%, and for CRE vs. non-infected patients was 9.61%. After adjustment for baseline variables, the HRs for mortality were 1.87 (95% CI, 0.99–3.50; p 0.06) and 3.65 (95% CI, 2.29–5.82; p < 0.001), respectively. However, when treatment-related time-dependent variables were added, the HR of CRE vs. CSE reduced to 1.44 (95% CI, 0.78–2.67; p 0.24). CRE infections are associated with significant attributable mortality and increased adjusted hazard of mortality when compared with CSE infections or patients without infection. Underlying patient characteristics and a delay in appropriate treatment play an important role in the CRE mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing.
- Author
-
Gatermann, Sören, Das, Shampa, Dubreuil, Luc, Giske, Christian G., Kahlmeter, Gunnar, Lina, Gerard, Lindemann, Christoffer, MacGowan, Alasdair, Meletiadis, Joseph, Rossolini, Gian Maria, Turnidge, John, and Cantón, Rafael
- Subjects
- *
MICROBIAL sensitivity tests , *NATURAL immunity - Published
- 2022
- Full Text
- View/download PDF
6. Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection.
- Author
-
Merino, Paloma, Guinea, Jesús, Muñoz-Gallego, Irene, González-Donapetry, Patricia, Galán, Juan Carlos, Antona, Nerea, Cilla, Gustavo, Hernáez-Crespo, Silvia, Díaz-de Tuesta, José Luis, Gual-de Torrella, Ana, González-Romo, Fernando, Escribano, Pilar, Sánchez-Castellano, Miguel Ángel, Sota-Busselo, Mercedes, Delgado-Iribarren, Alberto, García, Julio, Cantón, Rafael, Muñoz, Patricia, Folgueira, María Dolores, and Cuenca-Estrella, Manuel
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *VIRUS diseases - Abstract
The standard RT-PCR assay for coronavirus disease 2019 (COVID-19) is laborious and time-consuming, limiting testing availability. Rapid antigen-detection tests are faster and less expensive; however, the reliability of these tests must be validated before they can be used widely. The objective of this study was to determine the performance of the Panbio™ COVID-19 Ag Rapid Test Device (PanbioRT) (Abbott) in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in nasopharyngeal swab specimens. This prospective multicentre study was carried out in ten Spanish university hospitals and included individuals with clinical symptoms or epidemiological criteria of COVID-19. Only individuals with ≤7 days from the onset of symptoms or from exposure to a confirmed case of COVID-19 were included. Two nasopharyngeal samples were taken to perform the PanbioRT as a point-of-care test and a diagnostic RT-PCR test. Among the 958 patients studied, 325 (90.5%) had true-positive results. The overall sensitivity and specificity for the PanbioRT were 90.5% (95%CI 87.5–93.6) and 98.8% (95%CI 98–99.7), respectively. Sensitivity in participants who had a threshold cycle (C T) < 25 for the RT-PCR test was 99.5% (95%CI 98.4–100), and in participants with ≤5 days of the clinical course it was 91.8% (95%CI 88.8–94.8). Agreement between techniques was 95.7% (κ score 0.90; 95%CI 0.88–0.93). The PanbioRT performs well clinically, with even more reliable results for patients with a shorter clinical course of the disease or a higher viral load. The results must be interpreted based on the local epidemiological context. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients.
- Author
-
López-Causapé, Carla, Maruri-Aransolo, Ainhize, Gomis-Font, María A., Penev, Iván, Castillo, María García, Mulet, Xavier, de Dios Caballero, Juan, Campo, Rosa del, Cantón, Rafael, and Oliver, Antonio
- Subjects
- *
CYSTIC fibrosis , *PSEUDOMONAS aeruginosa , *WHOLE genome sequencing , *GENOMICS , *PENICILLIN-binding proteins , *HEMODILUTION , *QUORUM sensing - Abstract
To evaluate the activity of cefiderocol against sequential P. aeruginosa isolates from chronically-infected cystic fibrosis patients as well as to investigate the potential mechanisms involved in resistance through whole genome sequencing. Three sequential P. aeruginosa isolates from each of 50 chronically-colonized cystic fibrosis patients were studied. MICs for novel and classical antipseudomonal agents were determined by broth microdilution and whole genome sequences (n = 150) were obtained to investigate the presence of mutations within a set of chromosomal genes involved in P. aeruginosa antibiotic resistance (n = 40) and iron uptake (n = 120). Cefiderocol showed the lowest MIC 50/90 values and its susceptibility rate was comparable to other novel antipseudomonal agents. Clinical resistance was documented in 9 isolates from 6 patients. Resistance genes associated with a statistically significant increase in cefiderocol MICs included ampC, pmrAB, galU, fusA1 and those coding the penicillin-binding proteins PBP2 and PBP3. Likewise, mutations within several genes participating in different iron-uptake systems were found to be significantly associated with resistance, including genes participating in the pyochelin and pyoverdin biosynthesis and several tonB -dependent receptors. Mutator and small colony variants isolates were also associated with increased cefiderocol MICs. Cefiderocol resistance is modulated by a complex mutational resistome, potentially conferring cross-resistance to novel beta-lactam beta-lactamase combinations, as well as an extended list of mutated iron-uptake genes. Monitoring the acquisition of mutations in all these genes will be helpful to guide treatments and mitigate the emergence and spread of resistance to this novel antibiotic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. SARS-CoV-2 antibodies and utility of point of care testing in Health Care Workers from a spanish University Hospital in Madrid.
- Author
-
Rodríguez-Domínguez, Mario, Romero-Hernández, Beatriz, Marcos-Mencía, Daniel, Fernandez-Escribano, Marina, Ferré-Masferrer, Montserrat, Galán, Juan Carlos, and Cantón, Rafael
- Subjects
- *
MEDICAL personnel , *POINT-of-care testing , *SARS-CoV-2 , *UNIVERSITY hospitals , *MEDICAL care - Published
- 2021
- Full Text
- View/download PDF
9. Ultra-rapid flow cytometry assay for colistin MIC determination in Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii.
- Author
-
Fonseca e Silva, Daniela, Andrade, Ferdinando F., Gomes, Rosário, Silva-Dias, Ana, Martins-Oliveira, Inês, Pérez-Viso, Blanca, Ramos, Maria Helena, Rodrigues, Acácio G., Cantón, Rafael, and Pina-Vaz, Cidália
- Subjects
- *
PSEUDOMONAS aeruginosa , *FLOW cytometry , *DIFFERENCE operators , *ACINETOBACTER baumannii , *MICROBIAL sensitivity tests - Abstract
Both EUCAST and CLSI recommend broth microdilution for antimicrobial susceptibility testing of colistin, but this method is cumbersome and takes 16-24 h to give results. Our objective was to evaluate a rapid quantitative colistin MIC susceptibility assay based on flow cytometry analysis (FASTcolistin MIC) in comparison with standard broth microdilution assay. One hundred and sixteen Gram-negative bacilli (78 Enterobacterales, 28 Pseudomonas aeruginosa and 10 Acinetobacter baumannii) were studied in parallel using standard broth microdilution following EUCAST recommendations and FASTcolistin MIC kit. In the last one, a bacteria suspension (0.5 MacFarland) was prepared, diluted in Muller-Hinton broth, incubated in the susceptibility panel containing different colistin concentrations (range 0.125-64 mg/L) with a fluorescent probe and incubated 1 h at 35ºC. After that, a flow cytometry analysis using CytoFLEX (Beckmam) was performed. Using a dedicated software (BioFAST) an automated MIC result was obtained after 1.5 h. Performance evaluation was performed according to the ISO standard 20776-2. Reproducibility and repeatability, categorical (CA) and essential agreement (EA), and lot-to-lot variation and operator-to-operator variability, as well as time to results were determined. Overall, 100% CA (CI 97-100%) and 95.7% EA (CI 90-98%) was obtained with high repeatability (100%; CI 80-100%)and reproducibility (97%; (CI 83-99%)). Absence of lot-to-lot variations or differences in the operators' performance was observed. FASTcolistin MIC is an accurate, reliable and ultra-rapid method (1 h incubation versus 24 h) for susceptibility testing of colistin of common Gram-negative bacilli recovered in clinical laboratories. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.